Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Samsung Bioepis Reports Year Over Year Revenue Growth of 31%

Apr 24, 2024

Samsung Biologics revealed in its Q1 2024 Earnings that its subsidiary Samsung Bioepis has experienced year over year revenue growth of 31% and year over year operating profit of 6%, driven by sales expansion of its newly launched products.

Biosimilar highlights for Q1 2024 are reported to be the EC approval in April 2024 of Pyzchiva® (SB17, biosimilar to Janssen’s Stelara® (ustekinumab)); the Korean approvals of EpzystekTM (SB17, ustekinumab) in April 2024, Afilivu® (SB15, biosimilar to Regeneron’s Eylea® (aflibercept)) in February 2024, and Episcli® (SB12, biosimilar to Alexion’s Soliris® (eculizumab)) in January 2024; the initiation of a global phase 1 clinical trial for SB27 (biosimilar to MSD’s Keytruda® (pembrolizumab)) in February 2024; and commencement of direct sales in Korea of SB2 (infliximab), SB4 (etanercept) and SB5 (adalimumab).